Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Suruchi Salgar"'
Autor:
Neil A. O’Brien, Martina S. J. McDermott, Dylan Conklin, Tong Luo, Raul Ayala, Suruchi Salgar, Kevin Chau, Emmanuelle DiTomaso, Naveen Babbar, Faye Su, Alex Gaither, Sara A. Hurvitz, Ronald Linnartz, Kristine Rose, Samit Hirawat, Dennis J. Slamon
Publikováno v:
Breast Cancer Research, Vol 22, Iss 1, Pp 1-17 (2020)
Abstract Background Combined targeting of CDK4/6 and ER is now the standard of care for patients with advanced ER+/HER2− breast cancer. However, acquired resistance to these therapies frequently leads to disease progression. As such, it is critical
Externí odkaz:
https://doaj.org/article/2ebab795d742494f80b2463e971ee39c
Publikováno v:
Translational Research. 252:34-44
Overactive inflammatory responses are central to the pathophysiology of many hemolytic conditions including sickle cell disease. Excessive hemolysis leads to elevated serum levels of heme due to saturation of heme scavenging mechanisms. Extracellular
Autor:
Dylan Conklin, Neil A. O'Brien, S Hurvitz, M McDermott, Shawnt Issakhanian, Suruchi Salgar, DJ Slamon, Tong Luo, Raul Ayala
Publikováno v:
Cancer Research. 79:P6-17
Background: Pharmacologically targeting the HER2 oncoprotein provides clinical benefit for patients with HER2-amplified cancers. However, a significant number of patients do not respond to the currently approved HER2-targeted therapies, despite carry
Autor:
Tong Luo, Raul Ayala, Faye Su, M McDermott, Naveen Babbar, Dylan Conklin, Alex Gaither, Neil A. O'Brien, Kristine Rose, Sara A. Hurvitz, Samit Hirawat, Suruchi Salgar, Emmanuelle DiTomaso, Dennis J. Slamon, Kevin Chau, Ronald Linnartz
Publikováno v:
Breast cancer research : BCR, vol 22, iss 1
Breast Cancer Research, Vol 22, Iss 1, Pp 1-17 (2020)
Breast Cancer Research : BCR
Breast Cancer Research, Vol 22, Iss 1, Pp 1-17 (2020)
Breast Cancer Research : BCR
BackgroundCombined targeting of CDK4/6 and ER is now the standard of care for patients with advanced ER+/HER2− breast cancer. However, acquired resistance to these therapies frequently leads to disease progression. As such, it is critical to identi
Autor:
DJ Slamon, Tong Luo, V Rezek, S Kitchen, C Horak, M McDermott, Raul Ayala, U Dugan, Suruchi Salgar, D Conklin, NA O'Brien
Publikováno v:
Cancer Research. 79:P4-06
Background: Recent advances in the field of cancer immunotherapy have increased demand for reliable preclinical models to inform patient selection and rational drug combination strategies. The development of the bone marrow-liver-thymus (BLT) mouse m
Autor:
Alex Gaither, Dylan Conklin, Ronald Linnartz, Dennis J. Slamon, Raul Ayala, Suruchi Salgar, Kristine Rose, Emmanuelle DiTomaso, Sara A. Hurvitz, Tong Luo, Samit Hirawat, M McDermott, Naveen Babbar, Faye Su, Neil A. O'Brien
Publikováno v:
Cancer Research. 79:3825-3825
Addition of CDK4/6 inhibitors such as palbociclib, ribociclib or abemaciclib to endocrine-based therapies significantly improves progression-free and in some subgroups, overall survival in patients with advanced estrogen receptor-positive (ER+) breas